Microenvironmental abnormalities induced by viral cooperation: Impact on lymphomagenesis

Engels, 2007, Infectious agents as causes of non-Hodkin Lymphoma, Cancer Epidemiol Biomark Prev, 16, 401, 10.1158/1055-9965.EPI-06-1056 Bouvard, 2009, A review of human carcinogens – Part B: biological agents, Lancet Oncol, 10, 321, 10.1016/S1470-2045(09)70096-8 Gopal, 2014, J Clin Oncol De Paoli, 2013, Carcinogenic viruses and solid cancers without sufficient evidence of causal association, Int J Cancer, 133, 1517, 10.1002/ijc.27995 De Paoli, 2014, Pathogenesis of HIV-associated cancer, J Clin Oncol, 10.1200/JCO.2014.56.0680 Marcucci, 2011, Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities, Blood, 117, 1792, 10.1182/blood-2010-06-275818 IARC, 2012 Carbone, 2014, Diagnosis and management of lymphomas and other cancers in HIV-infected patients, Nat Rev Clin Oncol, 11, 223, 10.1038/nrclinonc.2014.31 Castillo, 2014, Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies, Br J Haematol, 165, 300, 10.1111/bjh.12788 Boshoff, 2011, Unraveling virus-induced lymphomagenesis, J Clin Invest, 121, 838, 10.1172/JCI46499 Carbone, 2014, KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies, Int J Cancer Scott, 2014, The tumour microenvironment in B cell lymphomas, Nat Rev Cancer, 14, 517, 10.1038/nrc3774 Shirogane, 2012, Cooperation between different RNA virus genomes produces a new phenotype, Nat Commun, 3, 1235, 10.1038/ncomms2252 Shirogane, 2013, Cooperation: another mechanism of viral evolution, Trends Microbiol, 21, 320, 10.1016/j.tim.2013.05.004 Mesri, 2014, Human viral oncogenesis: a cancer hallmarks analysis, Cell Host Microbe, 15, 266, 10.1016/j.chom.2014.02.011 Rickinson, 2014, Co-infections, inflammation and oncogenesis: future directions for EBV research, Semin Cancer Biol, 26, 99, 10.1016/j.semcancer.2014.04.004 Gulley, 2008, Laboratory assays for Epstein-Barr virus-related disease, J Mol Diagn, 10, 279, 10.2353/jmoldx.2008.080023 Li, 2006, Detection of Epstein-Barr virus infection and gene expression in human tumors by microarray analysis, J Virol Methods, 133, 158, 10.1016/j.jviromet.2005.10.032 Carbone, 2012, Cancers related to viral agents that have a direct role in carcinogenesis: pathological and diagnostic techniques, J Clin Pathol, 65, 680, 10.1136/jclinpath-2012-200717 De Paoli, 2007, The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers, J Cancer Res Clin Oncol, 133, 809, 10.1007/s00432-007-0281-2 Carbone, 2009, HIV-associated lymphomas and gamma-herpesviruses, Blood, 113, 1213, 10.1182/blood-2008-09-180315 Carbone, 2005, Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma, J Mol Diagn, 7, 17, 10.1016/S1525-1578(10)60004-9 Chadburn, 2013, Molecular and immunohistochemical detection of Kaposi Sarcoma Herpesvirus/human herpesvirus-8, Methods Mol Biol, 999, 245, 10.1007/978-1-62703-357-2_18 Boulanger, 2005, Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells, Int J Cancer, 115, 511, 10.1002/ijc.20926 Sakakibara, 2011, Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies, J Interferon Cytokine Res, 31, 791, 10.1089/jir.2011.0043 Simonelli, 2009, Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection, J Med Virol, 81, 888, 10.1002/jmv.21349 Breen, 2011, B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma, Cancer Epidemiol Biomark Prev, 20, 1303, 10.1158/1055-9965.EPI-11-0037 Liapis, 2013, The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies, Blood, 122, 424, 10.1182/blood-2013-03-488171 Sica, 2008, Macrophage polarization in tumour progression, Semin Cancer Biol, 18, 349, 10.1016/j.semcancer.2008.03.004 Bortolin, 2012, Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin-7, Cytokine, 60, 90, 10.1016/j.cyto.2012.06.022 Yang, 2013, Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection, J Immunol Methods, 391, 174, 10.1016/j.jim.2013.03.001 Bagasra, 1994, In situ polymerase chain reaction and HIV-1, Clin Lab Med, 14, 351, 10.1016/S0272-2712(18)30383-4 Huysentruyt, 2010, The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma, J Leukoc Biol, 87, 627, 10.1189/jlb.0809564 Coupland, 2011, The challenge of the microenvironment in B-cell lymphomas, Histopathology, 58, 69, 10.1111/j.1365-2559.2010.03706.x Lenz, 2008, Lymphoma/Leukemia molecular profiling project. Stromal gene signatures in large-B-cell lymphomas, N Engl J Med, 359, 2313, 10.1056/NEJMoa0802885 Preiksaitis, 2001, Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients, Clin Infect Dis, 33, S38, 10.1086/320903 Morscio, 2013, Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?, Clin Dev Immunol, 2013, 150835, 10.1155/2013/150835 Ishitsuka, 2014, Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma, Lancet Oncol, 15, e517, 10.1016/S1470-2045(14)70202-5 Matsuoka, 2007, Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation, Nat Rev Cancer, 7, 270, 10.1038/nrc2111 Tedeschi, 2001, Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma, J Clin Microbiol, 39, 4269, 10.1128/JCM.39.12.4269-4273.2001 Berretta, 2011, Hepatocellular carcinoma in HIV-infected patients: check early, treat hard, Oncologist, 16, 1258, 10.1634/theoncologist.2010-0400 Terrier, 2013, Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study, J Acquir Immune Defic Syndr, 63, 249, 10.1097/QAI.0b013e31828a77f0 Pagano, 2004, Infectious agents and cancer: criteria for a causal relation, Semin Cancer Biol, 14, 453, 10.1016/j.semcancer.2004.06.009 MacLeod, 2008, Human leukemia and lymphoma cell lines as models and resources, Curr Med Chem, 15, 339, 10.2174/092986708783497319 Carbone, 2010, Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines, AIDS, 24, 479, 10.1097/QAD.0b013e3283365395 Carbone, 2000, Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma, Leukemia, 14, 1301, 10.1038/sj.leu.2401802 Mack, 2008, EBV is necessary for proliferation of dually infected primary effusion lymphoma cells, Cancer Res, 68, 6963, 10.1158/0008-5472.CAN-08-0627 da Silva, 2011, HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies, Cancer Lett, 305, 175, 10.1016/j.canlet.2011.02.007 Münz, 2014, Viral infections in mice with reconstituted human immune system components, Immunol Lett, 161, 118, 10.1016/j.imlet.2014.05.012 White, 2012, EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors, J Clin Invest, 122, 1487, 10.1172/JCI58092 Wang, 2014, Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection, Proc Natl Acad Sci U S A, 111, 3146, 10.1073/pnas.1318175111 Van Baarle, 2002, Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma, J Infect Dis, 186, 405, 10.1086/341460 Piriou, 2008, Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection, Clin Infect Dis, 46, 313, 10.1086/524079 Piriou, 2004, Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma, J Immunol, 172, 6931, 10.4049/jimmunol.172.11.6931 Richard, 2010, Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus-infected patients before and after antiretroviral therapy, J Infect Dis, 202, 1424, 10.1086/656479 Seaberg, 2010, Multicenter AIDS Cohort Study (MACS). Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007, Cancer, 116, 5507, 10.1002/cncr.25530 Engels, 2007, Kaposi sarcoma-associated herpesvirus in non-Hodgkin lymphoma and reactive lymphadenopathy in Uganda, Hum Pathol, 38, 308, 10.1016/j.humpath.2006.08.009 Scala, 1993, Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1, J Virol, 67, 2853, 10.1128/JVI.67.5.2853-2861.1993 Lazzi, 2002, Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: implications for disease pathogenesis, Hum Pathol, 33, 723, 10.1053/hupa.2002.125372 Colombrino, 2004, Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells, Exp Cell Res, 295, 539, 10.1016/j.yexcr.2004.01.018 Chen, 2013, PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies, Clin Cancer Res, 19, 3462, 10.1158/1078-0432.CCR-13-0855 Planès, 2014, HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms, J Virol, 88, 6672, 10.1128/JVI.00825-14 Zenger, 2002, Injection of human primary effusion lymphoma cells or associated macrophages into severe combined immunodeficient mice causes murine lymphomas, Cancer Res, 62, 5536 Romagnani, 1994, Th1 versus Th2 responses in AIDS, Curr Opin Immunol, 6, 616, 10.1016/0952-7915(94)90150-3 Kondo, 2006, EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells, Cancer Res, 66, 9870, 10.1158/0008-5472.CAN-06-1679 Merat, 2002, HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation, Int J Cancer, 97, 791, 10.1002/ijc.10086 Mercader, 2001, Induction of human immunodeficiency virus 1 replication by human herpesvirus 8, Arch Pathol Lab Med, 125, 785, 10.5858/2001-125-0785-IOHIVR Huang, 2001, Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses, J Biol Chem, 276, 48108, 10.1074/jbc.M106388200 Caccuri, 2012, HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2, Proc Natl Acad Sci U S A, 109, 14580, 10.1073/pnas.1206605109 Giagulli, 2014, A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity, AIDS, 28, 2355, 10.1097/QAD.0000000000000423 Sun, 1998, A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus, Proc Natl Acad Sci U S A, 95, 10866, 10.1073/pnas.95.18.10866 Xu, 2007, Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpes virus lytic replication in primary effusion lymphomas, J Virol, 81, 6068, 10.1128/JVI.02743-06 Jiang, 2008, Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma, PLoS ONE, 3, e1569, 10.1371/journal.pone.0001569 Spadavecchia, 2010, Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signalling pathway in coinfected cells, J Virol, 84, 10488, 10.1128/JVI.00894-10 Godfrey, 2005, Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA, Blood, 105, 2510, 10.1182/blood-2004-08-3052 Caselli, 2001, Human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus) ORF50 interacts synergistically with the tat gene product in transactivating the human immunodeficiency virus type 1 LTR, J Gen Virol, 82, 1965, 10.1099/0022-1317-82-8-1965 Karijolich, 2014, Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2, J Virol, 88, 7024, 10.1128/JVI.00931-14 de Oliveira, 2010, NF-kappaB signaling modulation by EBV and KSHV, Trends Microbiol, 18, 248, 10.1016/j.tim.2010.04.001 Trivedi, 2004, Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression, Blood, 103, 313, 10.1182/blood-2003-05-1710 Kiss, 2003, T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines, Proc Natl Acad Sci U S A, 100, 4813, 10.1073/pnas.0730710100 Bentz, 2014, KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation, Virology, 448, 293, 10.1016/j.virol.2013.10.018 Lester, 2014, Toll-like receptors in antiviral innate immunity, J Mol Biol, 426, 1246, 10.1016/j.jmb.2013.11.024 Iskra, 2010, Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus, J Virol, 84, 3612, 10.1128/JVI.01400-09 Bussey, 2014, The gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 modulate the Toll-like receptor-induced proinflammatory cytokine response, J Virol, 88, 9245, 10.1128/JVI.00841-14 Gopal, 2014, Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort, Clin Infect Dis, 59, 279, 10.1093/cid/ciu270 Uldrick, 2012, Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy, J Clin Oncol, 30, 1476, 10.1200/JCO.2011.39.6853 Fang, 2013, Targeting the tumor microenvironment: from understanding pathways to effective clinical trials, Cancer Res, 73, 4965, 10.1158/0008-5472.CAN-13-0661 Jain, 2013, Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers, J Clin Oncol, 31, 2205, 10.1200/JCO.2012.46.3653